Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716002 | 0.89 | MAPKAPK2 (0.42) | MAPKAPK2MAPK10ABL1BCDIN3D | |
| SCHEMBL4719546 | 0.88 | MAPKAPK2 (0.41) | TRPV1MAPKAPK2MAPK10ABL1BCDIN3D | |
| SCHEMBL4718707 | 0.85 | TRPV1 (0.44) | TRPV1RAF1BRAFMAPK10BCDIN3D | |
| SCHEMBL4718655 | 0.84 | TRPV1 (0.59) | TRPV1RAF1BRAFABL1 | |
| SCHEMBL4715897 | 0.81 | TRPV1 (0.44) | TRPV1MAPKAPK2MAPK10 | |
| SCHEMBL4715985 | 0.81 | MAPK10 (0.44) | TRPV1MAPKAPK2MAPK10ABL1 | |
| SCHEMBL4717889 | 0.78 | MAPK10 (0.51) | TRPV1MAPKAPK2MAPK10ABL1 | |
| SCHEMBL4717911 | 0.77 | TRPV1 (0.48) | TRPV1MAPKAPK2MAPK10ABL1 | |
| SCHEMBL4716131 | 0.77 | TRPV1 (0.62) | TRPV1MAPK10 | |
| SCHEMBL4718620 | 0.77 | TRPV1 (0.50) | TRPV1MAPKAPK2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442701-B2 | Amino-heterocycles as VR-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1562934-B1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | TRPV1 40/4885MAPKAPK2 3284/4885RAF1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.